Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

Neurology

Volumn 76, Issue 8 SUPPL. 3, 2011, Pages

  Mehling, M ^a   Johnson, T A ^b   Antel, J ^b   Kappos, L ^a   Bar Or, A ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; INFLUENZA VACCINE; PLACEBO; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

BINDING AFFINITY; BRONCHITIS; CELL MIGRATION; CLINICAL IMMUNOLOGY; CLINICAL TRIAL (TOPIC); DEATH; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; T LYMPHOCYTE; VACCINATION;

EID: 79952026310     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820db341     Document Type: Article

References (69)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747. (Pubitemid 40563183)
2. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969. (Pubitemid 29132605)
3. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008;28:29-45. (Pubitemid 351273082)
4. Cohen J, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular Interferon β-1a: patient-reported indices for multiple sclerosis (PRIMUS)-activities results from a phase III study (TRANSFORMS). Neurology 2010;74(suppl 2):A543.
5. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140. (Pubitemid 44394919)
6. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
7. Adachi K, Chiba K. FTY720 story: its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem 2007;1:11-12.
8. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 2004;15:513-520. (Pubitemid 38953947)
9. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 2007;64:2270-2284. (Pubitemid 47347954)
10. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-21457. (Pubitemid 34952287)
11. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003;554:189-193. (Pubitemid 37324838)
12. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009;78:743-768.
13. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8:1337-1344. (Pubitemid 350131171)
14. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005;5:560-570. (Pubitemid 40961333)
15. Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005;128:1747-1763.
16. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9:393-407.
17. von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med 2000;343:1020-1034.
18. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360. (Pubitemid 38133663)
19. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-553.
20. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-5044.
21. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
22. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532-537. (Pubitemid 38509722)
23. Francis GS, Kappos L, O'Connor P, et al. Lymphocytes and fingolimod - temporal pattern and relationship with infections. Mult Scler 2010;16:S146.
24. Johnson TA, Shames I, Keezer M, et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol 2010;137:15-20.
25. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
26. Johnson TA, Lapierre Y, Bar-Or A, Antel J. Distinct properties of circulating CD8+ T cells in FTY720 treated multiple sclerosis patients. Arch Neurol 2010;67:1449-1455.
27. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
28. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-523.
29. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009;132:3329-3341.
30. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-104. (Pubitemid 29186827)
31. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-155. (Pubitemid 351186376)
32. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-1175. (Pubitemid 47530640)
33. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010;75:403-410.
34. Bohler T, Schutz M, Budde K, Neumayer HH, Waiser J. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. Int Immunopharmacol 2007;7:88-95. (Pubitemid 44856391)
35. Durafourt BA, Lambert C, Johnson TA, Blain M, Bar-Or A, Antel JP. Differential responses of human microglia and blood-derived myeloid cells to FTY720. J Neuroimmunol 2011;230:10-16.
36. Han S, Zhang X, Wang G, et al. FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 2004;104:4129-4133. (Pubitemid 39620165)
37. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000;18:10-18. (Pubitemid 30064888)
38. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-231. (Pubitemid 19190915)
39. Collins W, Cohens JA, O'Connor PW, et al. Long-term safety of oral (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies. Mult Scler 2010;16:S295.
40. Garber K. Infections cast cloud over Novartis' MS therapy. Nat Biotechnol 2008;26:844-845.
41. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79.
42. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207.
43. Walsh KB, Marsolais D, Welch MJ, Rosen H, Oldstone MB. Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. Virology 2010;397:260-269.
44. Kersh EN, Luo W, Adams DR, et al. Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques. J Antimicrob Chemother 2009;63:758-762.
45. Schmouder R, Boulton C, Wang N, David O. Effects of fingolimod on antibody response following steady state dosing in healthy volunteers: a 4-week, randomized, placebo-controlled study. Mult Scler 2010;16:S135.
46. Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated patients. Ann Neurol 2010 Dec 13 [Epub ahead of print].
47. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 2008;28:122-133.
48. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration J Biol Chem 2004;279:15396-15401.
49. Cinamon G, Matloubian M, Lesneski MJ, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5:713-720. (Pubitemid 39023303)
50. Vora KA, Nichols E, Porter G, et al. Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement. J Leukoc Biol 2005;78:471-480. (Pubitemid 41061319)
51. Allende ML, Tuymetova G, Lee BG, Bonifacino E, Wu YP, Proia RL. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med 2010;207:1113-1124.
52. Papadopoulos D, Rundle J, Patel R, et al. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 2010;88:346-359.
53. Singer II, Tian M, Wickham LA, et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol 2005;175:7151-7161. (Pubitemid 41713408)
54. Michaud J, Im DS, Hla T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 2010;184:1475-1483.
55. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 2008;102:950-958. (Pubitemid 351591554)
56. Weigert A, Johann AM, von Knethen A, Schmidt H, Geisslinger G, Brune B. Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood 2006;108:1635-1642. (Pubitemid 44316132)
57. Allende ML, Zhou D, Kalkofen DN, et al. S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. Faseb J 2008;22:307-315.
58. Jenne CN, Enders A, Rivera R, et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med 2009;206:2469-2481.
59. Hwang SJ, Kim JH, Kim HY, Kim S, Chung DH. FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration. Lab Invest 2010;90:9-19.
60. Czeloth N, Bernhardt G, Hofmann F, Genth H, Forster R. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J Immunol 2005;175:2960-2967. (Pubitemid 41170513)
61. Idzko M, Hammad H, van Nimwegen M, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006;116:2935-2944. (Pubitemid 44684478)
62. Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 2008;173:1143-1152.
63. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682-2694.
64. Jung CG, Kim HJ, Miron VE, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007;55:1656-1667. (Pubitemid 47612852)
65. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71. (Pubitemid 351240552)
66. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323:626-635. (Pubitemid 350005137)
67. Osinde M, Mullershausen F, Dev KK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 2007;52:1210-1218. (Pubitemid 46546406)
68. Van Doorn R, Van Horssen J, Verzijl D, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010;58:1465-1476.
69. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 2010;41:368-374.